Skip to main content
Premium Trial:

Request an Annual Quote

Graham Dixon Joins Galapagos as CSO, William Rohn to Retire from Biogen Idec, Joseph Shaw Named CEO of OpGen, and Others

Graham Dixon is the new CSO of Galapagos Genomics, the company said yesterday. He joins Galapagos from Entomed in Franceand F2G in the UK, where he was CSO simultaneously. Dixonholds a PhD in biochemistry from the Universityof Swanseain Wales.


William Rohn will retire as chief operating officer of Biogen Idec, effective Jan. 31 2005, the company said on Monday. His duties will be taken over by CEO James Mullen and other senior managers starting this week.


Joseph Shaw has become CEO of OpGen, the DNA analysis company said on Monday. He also joins the company's board of directors. Previously, Shaw was president of Bank On A Cure, a global study project of the International Myeloma Foundation and a myeloma-specific cancer patient DNA bank.


Frank Douglas has been appointed to fill a vacancy on the board of directors of Gene Logic. Until his recent retirement, Douglaswas executive vice president, drug innovation & approval and CSO of Aventis Pharma AG, where he oversaw Aventis' worldwide pharmaceutical research and development activities and was a member of the board of management of parent firm Aventis SA.


Randall Murch has been named associate director for research program development at Virginia Tech, where he will be responsible for strategic planning, as well as initiating and fostering research relationships between federal, state and local agencies, Virginia Tech, and centers that focus on life science and bio-security. As part of his duties, Murch will work closely with The Institute for Genomic Research, which has a recently formed strategic relationship with the university. He joins Virginia Tech from the Institute for Defense Analyses.


Tony Hunter and Anthony Pawson have been awarded the 2004 Louisa Gross Horwitz Prize from Columbia University. The researchers, which will receive their award in Feb. 2005, received the award "in recognition of their discoveries in understanding protein-tyrosine phosphorylation," Columbiasaid. Hunter is the American Cancer Society professor of molecular and cell biology at the Salk Institute for Biological Studies in San Diego. Pawson is a senior investigator and director of research at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital in Toronto, and a professor of medical genetics and microbiology at the Universityof Toronto.


Humberto Reyes has been appointed senior vice president of operations for Cepheid. He previously served as operations consultant for Brownsboro Group, a biotech regulatory and operations consulting company. Reyes also has held senior-level positions with Experttech Associates and Oxis Health Products.


TM Bioscience has appointed Paul Lucas chairman of the company's board of directors. Lucas is currently president and CEO of GlaxoSmithKline Canada and has served as an independent director of TM since 2002. The Toronto-based firm also announced that Neil M. Reid was appointed vice chairman and Michael Mueller was appointed to the board of directors. Reid has served as a director of TM since 2000 and is currently senior vice president of Protana. Mueller currently serves as president and CEO of MDS Capital.


ArdenBement, Jr., has been appointed by President Bush as the 12th director of the National Science Foundation. He has served as acing director of the agency since Feb. 22, 2004. The Senate confirmed Bement on Nov. 20. He has served as director of the National Institute of Standards and Technology since 2001, but resigned that post concurrent with his appointment as NSF director. Bement's term as NSF director is for 6 years.


Julia Hunter has retired as executive president and a director of Applied DNA Sciences "to pursue family matters," the company said last week. Applied DNA Sciences uses DNA as a tag for identification to prevent fraud.


Thomas Heydler has been appointed as CEO of Definiens, the Munich-based company said last week. Prior to joining Definiens, he was president and CEO of InterPro Business Solutions and Barcelona Design in the US.


Gary Mecklenburg has been elected to the board of directors of Becton Dickinson, the company said last week.  Mecklenburg is currently President and CEO of Northwestern Memorial Hospital in Chicago. He holds a BA from NorthwesternUniversityand an MBA from the Universityof Chicago.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.